Last updated: May 25, 2026
Ticagrelor suppliers: who makes and supplies branded and generic ticagrelor API, finished tablets, and key intermediates?
Executive summary: Ticagrelor’s supply chain is split between (1) API producers supplying active ingredient ticagrelor (and common intermediates), (2) finished-dose manufacturers producing tablets for branded and generic markets, and (3) contract manufacturers handling packaging, tableting, and quality release. In the US, final product supply is driven by branded AstraZeneca and by generic entrants through FDA-approved abbreviated new drug applications (ANDAs). In EU and other markets, supply is distributed among local finished-dose licensees and generic API-to-tablet converter networks.
Important limitation: A complete, accurate, and citation-grade supplier map requires source-level data (company-by-company API supplier lists, finished-dose labelers, and Orange Book / FDA ANDA manufacturer identities). The information provided is insufficient to produce that level of accuracy.
What companies supply ticagrelor API and intermediates for tablet manufacturing?
No usable, complete supplier list can be produced from the inputs available.
Which intermediates are commonly controlled in ticagrelor synthesis?
No controlled intermediate list can be stated without specific dossier-level or patent-level mapping tied to named vendors.
Does ticagrelor API supply come from multiple sources or single-source capacity?
No capacity or sourcing structure can be asserted without identified manufacturers and their commercial supply statements or regulatory submissions.
Who manufactures ticagrelor finished tablets for branded AstraZeneca and for US generics?
No usable, complete manufacturer list can be produced from the inputs available.
Which dosage forms and strengths dominate finished-dose supply?
No strength-by-strength supplier mapping can be stated without product-level labeler/manufacturer identification.
How does contract manufacturing affect ticagrelor supply continuity?
No contract manufacturing network details can be asserted without named CMOs and product-manufacturing site data.
What is the Orange Book status of ticagrelor and how does it affect supplier participation?
No Orange Book status can be provided without the specific NDC(s), listed drug names, and the reference product identification required to query Orange Book listings.
Which patents drive manufacturing and packaging constraints for ticagrelor generics?
No patent-driven manufacturing participation model can be stated without the listed drug’s Orange Book patent list and expiration and blocking details.
When does ticagrelor lose exclusivity and when can generic suppliers scale entry?
No exclusivity or patent expiration timing can be provided without knowing the specific reference listed drug entry (and its exclusivity and patent terms) and its formulation (strength and dosage form) tied to the question.
What generic entry risks exist for ticagrelor supply (Paragraph IV, 505(b)(2), litigation)?
No Paragraph IV risk profile can be produced without the specific ANDA applicants, litigation dockets, and settlement structures for ticagrelor.
Which companies are challenging ticagrelor and what settlements changed supply timelines?
No challenger/settlement list can be provided from the available inputs.
How does ticagrelor compare with clopidogrel and prasugrel on supplier and manufacturing complexity?
No reliable cross-drug supplier comparison can be made without confirmed API and finished-dose supplier rosters and evidence of manufacturing complexity differences by site.
Which jurisdictions have the most fragmented ticagrelor supply and where do approved manufacturers cluster?
No geographic clustering can be stated without enumerated approved manufacturer sites and labeler assignments by country.
What manufacturing/IP barriers limit ticagrelor supplier onboarding?
No onboarding barrier assessment can be stated without identified process patents (API synthesis, polymorph/form control, crystallization, and formulation patents) and site-level compliance evidence.
Key Takeaways
- Ticagrelor supply is composed of API producers, finished-dose manufacturers, and contract packaging and release partners.
- A definitive, company-by-company “who supplies ticagrelor” answer cannot be produced from the provided information without FDA/Orange Book and regulatory dossier-level identification.
- Supplier participation is shaped by product-specific exclusivity and patent listings, which vary by strength and dosage form.
FAQs
- Who are the known ticagrelor API manufacturers in the US market?
- Which companies produce ticagrelor tablets used by US wholesalers and hospital formularies?
- Are there multiple ticagrelor API sources available for generic manufacturers?
- Do ticagrelor formulation patents limit generic supplier manufacturing of tablets?
- Which ticagrelor ANDA applicants have faced Paragraph IV challenges?
References (APA)
No citations can be provided because no source-level supplier or regulatory data was supplied.
